not tagged
chemocentryx
['chemocentryx']
chemocentryx reports safety results available from ongoing phase i trial of orally administered pd-l1 inhibitor, ccx559, at the 2022 american society of clinical oncology (asco) annual meeting - consistent with approved antibody inhibitors of pd-l1, ccx... 
CEO Of Digital Media Online